Levodopa inhalation - Acorda Therapeutics

Drug Profile

Levodopa inhalation - Acorda Therapeutics

Alternative Names: CVT-301; INBRIJA™; Inhaled L-dopa - Civitas Therapeutics

Latest Information Update: 14 Jun 2017

Price : $50

At a glance

  • Originator Civitas Therapeutics
  • Developer Acorda Therapeutics
  • Class Antiparkinsonians; Catecholamines; Small molecules
  • Mechanism of Action Dopamine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Parkinson's disease
  • Phase I Asthma; Smoking withdrawal

Most Recent Events

  • 05 Jun 2017 Interim adverse events data from a phase III trial in Parkinson's disease released by Acorda Therapeutics
  • 05 Jun 2017 Updated efficacy and adverse events data from the phase III SPAN-PD trial in Parkinson's disease presented at the International Congress of Parkinson’s Disease and Movement Disorders (MDS-2017)
  • 01 May 2017 Acorda Therapeutics completes a phase-III trial in Parkinson's disease (Adjunctive treatment) in USA, Austria, Belgium, Czech Republic, France, Germany, Hungary, Israel, Italy, Poland, Romania, Serbia, Spain and United Kingdom (Inhalation) (NCT02352363)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top